MeMed and Invetech Partner to Commercialize Diagnostic Platform
3 reports, 1 independent
Updated Fri 00:00
No new developments lately
Reached 3 outlets in its first 24 hours
- Reports
- 3
- Developments
- 1
- Repetition
- 67%
New informationRepeats or wire copies
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
MeMed and Invetech announced a partnership to accelerate the commercialization of the MeMed Key™ diagnostic platform. The MeMed Key™ is a compact immunoassay platform designed to rapidly distinguish between bacterial and viral infections. Invetech will provide end-to-end engineering and manufacturing expertise, including regulatory testing and production process validation, to support the platform's commercialization.
Why it matters
The collaboration combines MeMed’s expertise in host-response diagnostics with Invetech’s experience in product development and commercialization. This partnership is intended to bring advanced diagnostic technology into clinical practice.
Who's involved
- Eran EdenCEO and Co-founder of MeMed
Keep exploring
The entities involved
-
Eran Eden
researcher
Nothing else this week.